GeneDx Holdings Corp. (NASDAQ:WGS) CFO Sells $1,430,264.88 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 15,516 shares of the company’s stock in a transaction on Wednesday, April 9th. The shares were sold at an average price of $92.18, for a total transaction of $1,430,264.88. Following the completion of the sale, the chief financial officer now directly owns 1,726 shares in the company, valued at approximately $159,102.68. This represents a 89.99 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Kevin Feeley also recently made the following trade(s):

• On Wednesday, March 26th, Kevin Feeley sold 8,746 shares of GeneDx stock. The shares were sold at an average price of $95.61, for a total value of $836,205.06.
• On Monday, March 17th, Kevin Feeley sold 3,749 shares of GeneDx stock. The stock was sold at an average price of $96.71, for a total value of $362,565.79.
• On Thursday, March 13th, Kevin Feeley sold 402 shares of GeneDx stock. The stock was sold at an average price of $90.05, for a total transaction of $36,200.10.
• On Monday, March 10th, Kevin Feeley sold 922 shares of GeneDx stock. The shares were sold at an average price of $94.72, for a total transaction of $87,331.84.
• On Wednesday, January 29th, Kevin Feeley sold 275 shares of GeneDx stock. The shares were sold at an average price of $78.48, for a total value of $21,582.00.

GeneDx Stock Up 4.3 %

WGS stock opened at $96.63 on Friday. The stock has a market cap of $2.71 billion, a P/E ratio of -49.30 and a beta of 1.93. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. The stock’s fifty day simple moving average is $90.43 and its two-hundred day simple moving average is $78.11. GeneDx Holdings Corp. has a 1-year low of $8.63 and a 1-year high of $115.60.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.66. The company had revenue of $95.64 million for the quarter, compared to the consensus estimate of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. Analysts expect that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Institutional Trading of GeneDx

Large investors have recently bought and sold shares of the company. MCF Advisors LLC increased its holdings in GeneDx by 107.7% in the 4th quarter. MCF Advisors LLC now owns 351 shares of the company’s stock worth $27,000 after acquiring an additional 182 shares during the last quarter. Sterling Capital Management LLC increased its stake in shares of GeneDx by 877.8% in the fourth quarter. Sterling Capital Management LLC now owns 352 shares of the company’s stock worth $27,000 after purchasing an additional 316 shares in the last quarter. Global Retirement Partners LLC bought a new stake in shares of GeneDx in the fourth quarter valued at approximately $28,000. Lazard Asset Management LLC purchased a new stake in shares of GeneDx during the 4th quarter valued at approximately $35,000. Finally, Comerica Bank bought a new position in GeneDx in the 4th quarter worth approximately $50,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

WGS has been the topic of a number of research reports. TD Cowen upped their target price on GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research report on Tuesday, January 7th. The Goldman Sachs Group increased their price target on GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a research report on Wednesday, February 19th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $72.33.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.